Drug deaths in the United States are more than 27 times higher than in Italy and Japan, which have the lowest rates, and are double the rates of Finland and Sweden, the countries with the next highest death rates.

In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug's maker.